85,132 results match your criteria prostate biopsy


Which measurement method should be used for prostate volume for PI-RADS? A comparison of ellipsoid and segmentation methods.

Clin Imaging 2021 Sep 21;80:454-458. Epub 2021 Sep 21.

Department of Radiology and Molecular Imaging, Oakland University William Beaumont School of Medicine, Royal Oak, MI, United States of America. Electronic address:

Purpose: Prostate volume and PSA density (PSAd) are important in the risk stratification of suspected prostate cancer (Pca). PI-RADS v2.1 allows for determining volume via segmentation or ellipsoid calculation. Read More

View Article and Full-Text PDF
September 2021

Tumor Targeting and Penetrating Biomimetic Mesoporous Polydopamine Nanoparticles Facilitate Photothermal Killing and Autophagy Blocking for Synergistic Tumor Ablation.

Acta Biomater 2021 Sep 22. Epub 2021 Sep 22.

Department of Clinical Immunology, Institute of Clinical Laboratory Medicine, Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, Dongguan, Guangdong, 523808, China. Electronic address:

The synergistic manipulation of autophagy blocking with tumor targeting and penetration effects to enhance cancer cell killing during photothermal therapy (PTT) remains a substantial challenge. Herein, we fabricated a biomimetic nanoplatform by precisely coating homologous prostate cancer cell membranes (CMs) onto the surface of mesoporous polydopamine nanoparticles (mPDA NPs) encapsulating the autophagy inhibitor chloroquine (CQ) for synergistically manipulating PTT and autophagy for anticancer treatment. The resulting biomimetic [email protected] NPs-CQ system could escape macrophage phagocytosis, overcome the vascular barrier, and home in the homologous prostate tumor xenograft with high tumor targeting and penetrating efficiency. Read More

View Article and Full-Text PDF
September 2021

COVID-19 pandemic impact on uro-oncological disease outcomes at an Italian tertiary referral center.

World J Urol 2021 Sep 25. Epub 2021 Sep 25.

Division of Urology, Department of Surgical Sciences - Urology, Città della Salute e della Scienza di Torino - Molinette Hospital, University of Turin, Turin, Italy.

Purpose: To assess differences in referral and pathologic outcomes for uro-oncology cases prior to and during the COVID pandemic, comparing clinical and pathological data of cancer surgeries performed at an academic referral center between 2019 and 2020.

Methods: We collected data of 880 prostate biopsies, 393 robot-assisted radical prostatectomies (RARP) for prostate cancer (PCa), 767 trans-urethral resections of bladder tumor (TURB) and 134 radical cystectomies (RC) for bladder cancer (BCa), 29 radical nephro-ureterectomies (RNU) for upper tract urothelial carcinoma, 130 partial nephrectomies (PN) and 12 radical nephrectomies (RN) for renal cancer, and 41 orchifunicolectomies for testicular cancer. Data of patients treated in 2019 (before COVID-19 pandemic) were compared to patients treated in 2020 (during pandemic). Read More

View Article and Full-Text PDF
September 2021

How I faced my prostate cancer: a molecular biologist's perspective.

NPJ Precis Oncol 2021 Sep 24;5(1):88. Epub 2021 Sep 24.

Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy.

View Article and Full-Text PDF
September 2021

Adjuvant Systemic Therapies for Patients with Renal Cell Carcinoma: Choosing Treatment Based on Patient-level Characteristics.

Eur Urol Oncol 2021 Sep 21. Epub 2021 Sep 21.

Division of Hematology and Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Simmons Comprehensive Cancer Center, Dallas, TX, USA; Division of Medical Oncology, Duke Department of Medicine, Durham, NC, USA; Duke Cancer Institute Center for Prostate & Urologic Cancers, Durham, NC, USA.

Motivated by recent presentation of the KEYNOTE-564 interim results for adjuvant pembrolizumab in clear-cell renal cell carcinoma, we discuss concepts that can guide patient-specific decision-making in selecting individuals for whom adjuvant therapies should be offered. Read More

View Article and Full-Text PDF
September 2021

[Very old patients in multidisciplinary team meeting in PACA: a one-year survey].

Bull Cancer 2021 Sep 21. Epub 2021 Sep 21.

Institut Paoli-Calmettes, oncologie médicale, 13000 Marseille, France.

Introduction: In 2011, 11% of all cancers were diagnosed in people over 85 years old. With the current aging of the French population associated with health progress, we will be confronted more and more frequently with the treatment of very old patients, and this until the horizon 2050, when the population over 75 years old will represent approximately 15% of the total French population (compared to 9.1% in 2015). Read More

View Article and Full-Text PDF
September 2021

Interreader agreement in evaluation of 68Ga-PSMA PET/CT at the time of initial staging: comparison of the three evaluation criteria in the pretreatment risk groups.

Nucl Med Commun 2021 Sep 23. Epub 2021 Sep 23.

Department of Nuclear Medicine, Dokuz Eylul University Faculty of Medicine, Izmir Department of Nuclear Medicine, Başakşehir Çam ve Sakura City Hospital, Istanbul Department of Urology, Dokuz Eylul University Faculty of Medicine Department of Pathology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey.

Objective: The aim of this study was to assess the interreader agreement in evaluation 68Ga-prostate-specific membrane antigen (PSMA) PET/CT according to three current criteria European association of nuclear medicine, PROMISE with miTNM, and PSMA-RADS in newly diagnosed prostate cancer (PC) patients.

Methods: The images of 101 patients who had been diagnosed with PC and underwent 68Ga-PSMA PET/CT at the time of initial staging were evaluated according to the three interpretation criteria by two nuclear medicine specialists. Local tumor, pelvic lymph node metastasis and distant metastasis were evaluated separately. Read More

View Article and Full-Text PDF
September 2021

Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications.

Virchows Arch 2021 Sep 24. Epub 2021 Sep 24.

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.

Cytokeratins (CKs) 5 and 6 are functionally unrelated but often analyzed together using bispecific antibodies in diagnostic immunohistochemistry. To better understand the diagnostic utility of CK5 or CK6 alone, tissue microarrays with > 15,000 samples from 120 different tumor types as well as 608 samples of 76 different normal tissues were analyzed by immunohistochemistry. In normal tissues, both CKs occurred in the squamous epithelium; CK5 dominated in basal and CK6 in suprabasal layers. Read More

View Article and Full-Text PDF
September 2021

Proteomic characterization of primary and metastatic prostate cancer reveals reduced proteinase activity in aggressive tumors.

Sci Rep 2021 Sep 23;11(1):18936. Epub 2021 Sep 23.

Department of Pathology, The John Hopkins Medical Institutions, 600 N. Wolfe Street, Baltimore, MD, 21224, USA.

Prostate cancer (PCa) is a heterogeneous group of tumors with variable clinical courses. In order to improve patient outcomes, it is critical to clinically separate aggressive PCa (AG) from non-aggressive PCa (NAG). Although recent genomic studies have identified a spectrum of molecular abnormalities associated with aggressive PCa, it is still challenging to separate AG from NAG. Read More

View Article and Full-Text PDF
September 2021

The Role of 3D Models Obtained from Multiparametric Prostate MRI in Performing Robotic Prostatectomy.

J Endourol 2021 Sep 24. Epub 2021 Sep 24.

Icahn School of Medicine at Mount Sinai, 5925, Urology, One Gustave L. Levy Place, Box 1272, New York, New York, United States, 10029-6574;

Background: mpMRI can provide important information for surgical planning, yet its interpretation is not immediate and imaging consultation at the time of surgery can result in interruptions and delay. The use of 3D models based on mpMRI, might obviate these issues. We aimed to evaluate the role of the prospective integration of 3D models from mpMRI in the robotic console in reducing the rate of PSMs. Read More

View Article and Full-Text PDF
September 2021

Infection Rate after Transperineal Prostate Biopsy with and without Prophylactic Antibiotics: Results from a Systematic Review and Meta-analysis of Comparative Studies.

J Urol 2021 Sep 24:101097JU0000000000002251. Epub 2021 Sep 24.

Department of Urology, A.O.U.I. Verona University, Verona, Italy.

Purpose: We performed a systematic review comparing the incidence infectious complications following transperineal prostate biopsy (TPB) in cases utilizing antibiotic prophylaxis (AP) to cases not utilizing antibiotic prophylaxis (NAP).

Materials And Methods: The incidences of complications were pooled using the Cochran-Mantel-Haenszel Method with the random effect model and expressed as risk ratio (RR). RR higher than 1 indicates an increased risk of complication in patients undergoing TPB without antibiotics. Read More

View Article and Full-Text PDF
September 2021

Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer.

J Urol 2021 Sep 24:101097JU0000000000002250. Epub 2021 Sep 24.

Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.

Aim: To compare cancer specific mortality (CSM) rates between radical prostatectomy (RP) vs. external beam radiotherapy (EBRT) in National Comprehensive Cancer Network (NCCN) high risk (HR) patients, as well as in Johns Hopkins University (JH) high-risk (HR) and very high risk (VHR) subgroups.

Materials And Methods: Within the Surveillance, Epidemiology, and End Results database (2010-2016), we identified 24,407 NCCN HR patients, of whom 10,300 (42%) vs 14,107 (58%) patients that qualified for JH HR and VHR, respectively. Read More

View Article and Full-Text PDF
September 2021

Optimizing Combined MRI Targeted and Systematic Biopsy Strategies: Sparing the mpMRI-Negative Transitional-Zone in Presence of Exclusively Peripheral mpMRI-Suspect Lesions.

J Urol 2021 Sep 24:101097JU0000000000002248. Epub 2021 Sep 24.

Martini-Klinik Prostate Cancer Center Hamburg-Eppendorf, Hamburg, Germany.

Objective: To assess whether sampling of the transitional-zone can be spared in patients with exclusively peripheral prostate cancer (PCa)-suspicious mpMRI lesions, who undergo combined mpMRI targeted (TBx) and systematic prostate biopsies (SBx).

Materials And Methods: Of 1,685 patients, who underwent extended SBx including transitional-zone sampling and had TBx of ≥1 lesion in the peripheral- and/or transitional-zone, we selected 863 patients with exclusively peripheral PCa-suspicious lesions and negative transitional-zone mpMRI. Clinically significant PCa (csPCa) was defined as Gleason score (GS) ≥3+4. Read More

View Article and Full-Text PDF
September 2021

Prostate Cancer Screening and Incidence Among Aging Persons Living with HIV.

J Urol 2021 Sep 24:101097JU0000000000002249. Epub 2021 Sep 24.

Icahn School of Medicine at Mt Sinai, New York, New York.

Introduction: The risk of prostate cancer among persons living with HIV (PWH) is not well understood and may be obscured by different opportunities for detection.

Methods: We identified 123,472 (37,819 PWH and 85,653 comparators) men enrolled in the Veterans Aging Cohort Study, a prospective national cohort of PWH and demographically-matched, uninfected comparators in 2000-2015. We calculated rates of PSA testing by HIV status and fit multivariable Poisson models comparing the rates of PSA testing, prostate biopsy, and cancer incidence. Read More

View Article and Full-Text PDF
September 2021

High Inter- and Intratumoral Variability of Ki67 Labeling Index in Newly Diagnosed Prostate Cancer with High Gleason Scores.

Pathobiology 2021 Sep 23:1-7. Epub 2021 Sep 23.

Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.

Background: The majority of studies investigating the role of Ki67 labeling index (LI) in prostate carcinoma (PC) focused on localized PC treated radically, where Ki67 LI is regarded as a prognostic marker. The relevance of Ki67 in advanced PC remains largely unexplored. While Gleason score is still one of the best indicators of clinical outcomes in PC, differences in progression-free survival and overall survival in patients with high Gleason scores suggest that additional factors are involved in tumor progression. Read More

View Article and Full-Text PDF
September 2021

Absolute choline tissue concentration mapping for prostate cancer localization and characterization using 3D H MRSI without water-signal suppression.

Magn Reson Med 2021 Sep 23. Epub 2021 Sep 23.

Department of Medical Imaging (Radiology), Radboud University Medical Center, Nijmegen, The Netherlands.

Purpose: Until now, H MRSI of the prostate has been performed with suppression of the large water signal to avoid distortions of metabolite signals. However, this signal can be used for absolute quantification and spectral corrections. We investigated the feasibility of water-unsuppressed MRSI in patients with prostate cancer for water signal-mediated spectral quality improvement and determination of absolute tissue levels of choline. Read More

View Article and Full-Text PDF
September 2021

Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer.

JAMA Oncol 2021 Sep 23. Epub 2021 Sep 23.

Department of Human Oncology, University of Wisconsin, Madison.

Importance: Luminal and basal subtypes of primary prostate cancer have been shown to be molecularly distinct and clinically important in predicting response to therapy. These subtypes have not been described in metastatic prostate cancer.

Objectives: To identify clinical and molecular correlates of luminal and basal subtypes in metastatic castration-resistant prostate cancer (mCRPC) and investigate differences in survival, particularly after treatment with androgen-signaling inhibitors (ASIs). Read More

View Article and Full-Text PDF
September 2021

Rapidly recurrent prostatic obstruction due to granulomatosis with polyangiitis.

Urol Case Rep 2021 Nov 7;39:101771. Epub 2021 Jul 7.

Anatpath, 120 Gardenvale Road, Gardenvale, VIC, 3185, Australia.

Granulomatosis with polyangiitis (GPA) is a rare cause of prostatitis. Our case illustrates a case of granulomatous prostatitis secondary to unrecognised GPA requiring multiple surgical interventions. The patient presented with lower urinary tract symptoms. Read More

View Article and Full-Text PDF
November 2021

Successful Treatment of Malignant Priapism by Radiotherapy: Report of a Case, Review of the Literature, and Treatment Recommendations.

Cureus 2021 Aug 18;13(8):e17287. Epub 2021 Aug 18.

Gippsland Radiation Oncology, Latrobe Regional Hospital, Traralgon, AUS.

Malignant priapism is a condition of painful induration and erection of the penis secondary to metastatic infiltration by a neoplasm. This condition is associated with a poor prognosis. We report on a case of an 87-year-old man who presented with a painful, partially erected penis subsequent to a diagnosis of metastatic Gleason 4+5 prostate cancer. Read More

View Article and Full-Text PDF

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection.

Onco Targets Ther 2021 15;14:4819-4832. Epub 2021 Sep 15.

Department of Medicine, Division of Hematology and Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Metastatic castration-resistant prostate cancer (mCRPC) is an aggressive and fatal disease with a median survival of 36 months. With the advent of genetic sequencing to identify individual genomic profiles and acquired tumor-specific pathways, targeted therapies have revolutionized cancer treatment, including the treatment strategy in mCRPC. Poly(adenosine 5'-diphosphate) ribose polymerase inhibitors (PARPi) are oral drugs that target mutations in the homologous recombination repair (HRR) pathway, which are found in approximately 27% of prostate cancer patients. Read More

View Article and Full-Text PDF
September 2021

Oncological and Functional Outcomes of Robot-Assisted Radical Prostatectomy in Kidney Transplant Recipients.

JSLS 2021 Jul-Sep;25(3)

Department of Urology, University of California Irvine.

Objective: Management of prostate cancer in kidney transplant recipients presents a unique surgical challenge due to the risk of direct or indirect injury to the transplanted kidney. Herein, we report the largest single center study of Robot-assisted Radical prostatectomy (RARP) in kidney transplant recipients.

Methods: Between Jan 2014-2019, 14 kidney transplant recipients with prostate cancer underwent RARP. Read More

View Article and Full-Text PDF
September 2021

Biologically informed deep neural network for prostate cancer discovery.

Nature 2021 Sep 22. Epub 2021 Sep 22.

Dana-Farber Cancer Institute, Boston, MA, USA.

The determination of molecular features that mediate clinically aggressive phenotypes in prostate cancer remains a major biological and clinical challenge. Recent advances in interpretability of machine learning models as applied to biomedical problems may enable discovery and prediction in clinical cancer genomics. Here we developed P-NET-a biologically informed deep learning model-to stratify patients with prostate cancer by treatment-resistance state and evaluate molecular drivers of treatment resistance for therapeutic targeting through complete model interpretability. Read More

View Article and Full-Text PDF
September 2021

A risk model for detecting clinically significant prostate cancer based on bi-parametric magnetic resonance imaging in a Japanese cohort.

Sci Rep 2021 Sep 22;11(1):18829. Epub 2021 Sep 22.

Department of Urology, Toranomon Hospital, 2-2-2- Toranomon, Minato-ku, Tokyo, 105-8470, Japan.

Selective identification of men with clinically significant prostate cancer (sPC) is a pivotal issue. Development of a risk model for detecting sPC based on the prostate imaging reporting and data system (PI-RADS) for bi-parametric magnetic resonance imaging (bpMRI) and clinical parameters in a Japanese cohort is expected to prove beneficial. We retrospectively analyzed clinical parameters and bpMRI findings from 773 biopsy-naïve patients between January 2011 and December 2016. Read More

View Article and Full-Text PDF
September 2021

Characteristics of α2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level.

Prostate 2021 Sep 21. Epub 2021 Sep 21.

Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan.

Background: The presence of glycosylated isoforms of prostate-specific antigen (PSA) in prostate cancer (PC) cells is a potential marker of their aggressiveness. We characterized the origin of α2,3-sialylated prostate-specific antigen (S23PSA) by tissue-based sialylation-related gene expression and studied the performance of S23PSA density (S23PSAD) alone and in combination with multiparametric magnetic resonance imaging (MRI) for the detection of clinically significant prostate cancer in men with elevated PSA.

Methods: Tissue-based quantification of S23PSA and sialyltransferase and sialidase gene expression was evaluated in 71 radical prostatectomy specimens. Read More

View Article and Full-Text PDF
September 2021

Diagnostic accuracy of magnetic resonance imaging targeted biopsy techniques compared to transrectal ultrasound guided biopsy of the prostate: a systematic review and meta-analysis.

Prostate Cancer Prostatic Dis 2021 Sep 21. Epub 2021 Sep 21.

Imperial Prostate. Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.

Background: Multiparametric MRI localizes cancer in the prostate, allowing for MRI guided biopsy (MRI-GB) 43 alongside transrectal ultrasound-guided systematic biopsy (TRUS-GB). Three MRI-GB approaches exist; visual estimation (COG-TB); fusion software-assisted (FUS-TB) and MRI 'in-bore' biopsy (IB-TB). It is unknown whether any of these are superior. Read More

View Article and Full-Text PDF
September 2021

Selective degradation of AR-V7 to overcome castration resistance of prostate cancer.

Cell Death Dis 2021 Sep 21;12(10):857. Epub 2021 Sep 21.

Affiliated Cancer Hospital & Institute of Guangzhou Medical University, 510095, Guangzhou, Guangdong, China.

Androgen receptor splice variant 7 (AR-V7), a form of ligand-independent and constitutively activating variant of androgen receptor (AR), is considered as the key driver to initiate castration-resistant prostate cancer (CRPC). Because AR-V7 lacks ligand-binding domain, the AR-targeted therapies that aim to inactivate AR signaling through disrupting the interaction between AR and androgen are limited in CRPC. Thus, the emergence of AR-V7 has become the greatest challenge for treating CRPC. Read More

View Article and Full-Text PDF
September 2021

The Anatomical Relationships in the Space of Retzius for Penile Implants: An MRI Analysis.

J Sex Med 2021 Sep 18. Epub 2021 Sep 18.

Male Sexual and Reproductive Medicine Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA. Electronic address:

Background: The 3-piece inflatable penile prosthesis includes an easy-to-use pump and fluid filled reservoir which is placed in either the space of Retzius (SOR) or in an alternative ectopic location. Reservoir placement in the SOR is a blind procedure despite the SOR being surrounded by many critical structures. To date only a handful of cadaveric studies have described the relevant anatomy. Read More

View Article and Full-Text PDF
September 2021

Expression and subcellular localization of Discoidin Domain Receptor 1 (DDR1) define prostate cancer aggressiveness.

Cancer Cell Int 2021 Sep 21;21(1):507. Epub 2021 Sep 21.

Department of Pathology, Wayne State University School of Medicine and Karmanos Cancer Institute, Scott Hall #8200, 540 E. Canfield St, Detroit, MI, 48201, USA.

Background: The Discoidin Domain Receptor 1 (DDR1) is one of the two members of a unique family of receptor tyrosine kinase receptors that signal in response to collagen, which has been implicated in cancer progression. Here, we examined the expression of DDR1 in prostate cancer (PCa), and assessed its potential value as a prognostic marker, as a function of grade, stage and other clinicopathologic parameters.

Methods: We investigated the association between the expression level and subcellular localization of DDR1 protein and PCa aggressiveness by immunohistochemistry, using tissue microarrays (TMAs) encompassing 200 cases of PCa with various Gleason scores (GS) and pathologic stages with matched normal tissue, and a highly specific monoclonal antibody. Read More

View Article and Full-Text PDF
September 2021

MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10 399 Tissue Samples.

Technol Cancer Res Treat 2021 Jan-Dec;20:15330338211043328

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Mucin 5AC (MUC5AC) belongs to the glycoprotein family of secreted gel-forming mucins and is physiologically expressed in some epithelial cells. Studies have shown that MUC5AC is also expressed in several cancer types suggesting a potential utility for the distinction of tumor types and subtypes. To systematically determine MUC5AC expression in normal and cancerous tissues, a tissue microarray containing 10 399 samples from 111 different tumor types and subtypes as well as 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry. Read More

View Article and Full-Text PDF
September 2021

An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer.

J Urol 2021 Sep 22:101097JU0000000000002205. Epub 2021 Sep 22.

Department of Urology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Purpose: Current guidelines do not provide strong recommendations on the preservation of the neurovascular bundles during RP in case of HR PCa and/or suspicious EPE. We aimed to evaluate when, in case of unilateral HR disease, contralateral NS should be considered or not.

Methods: Within a multi-institutional dataset we selected patients with unilateral HR PCa defined as: unilateral EPE and/or SVI on mpMRI or unilateral ISUP 4-5 or PSA ≥20 ng/ml. Read More

View Article and Full-Text PDF
September 2021